Purpose: To examine the effect of growth hormone (GH) treatment on physical performance in children with idiopathic short stature and normal GH secretion. Materials and Methods: A total of 24 children participated in the study (13 GH-treated, 11 non-treated, aged 8–13 y, 11 males and 13 females, Tanner stage 1–2). Participants performed a battery of motor skill performance tests (Eurofit), as well as the Wingate anaerobic test. Results: No statistically significant differences in any of the Eurofit physical fitness test results (eg, 20-m shuttle run 33.0 [15.1] vs 25.1 [21.0] laps in treated and nontreated participants, respectively, P = .25) or the Wingate anaerobic test were found between the groups (eg, peak power 5.0 [2.9] vs 3.9 [2.6] watts/kg in treated and nontreated participants, respectively, P = .2). Conclusions: Therapeutic usage of exogenous GH for pre and early pubertal children with idiopathic short stature and normal GH secretion was not associated with beneficial effects on physical performance indices. This suggests that the use of GH as a potential performance enhancing agent, in this age group, at least at commonly used doses, is not advantageous.

目的：检查生长激素（GH）治疗对特发性身材矮小和生长激素分泌正常的儿童身体机能的影响。材料和方法：共有 24 名儿童参与了研究（13 名接受 GH 治疗，11 名未接受治疗，8-13 岁，11 名男性和 13 名女性，Tanner 1-2 期）。参与者进行了一系列运动技能性能测试 (Eurofit) 以及 Wingate 无氧测试。结果：任何 Eurofit 体能测试结果均无统计学显着差异（例如，接受治疗和未接受治疗的参与者的 20 米穿梭跑分别为 33.0 [15.1] 和 25.1 [21.0] 圈， P = .25) 或 Wingate 无氧试验在组间进行（例如，治疗组和未治疗组的峰值功率分别为 5.0 [2.9] 和 3.9 [2.6] 瓦特/公斤，P  = .2）。结论：外源性GH治疗特发性身材矮小且GH分泌正常的青春期前和青春期早期儿童与身体机能指标的有益影响无关。这表明在这个年龄组中，至少在常用剂量下，使用 GH 作为潜在的性能增强剂是不利的。